Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes
NCT02721875 · Boehringer Ingelheim · PHASE1 · terminated · last registry update 2018-08-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Boehringer Ingelheim |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLK1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-07-26Results posted on the registry: Boehringer Ingelheim, BI 6727 (NCT00969553)
- 2019-02-08Results posted on the registry: Boehringer Ingelheim, Azacitidine + Volasertib (NCT01957644)
- 2019-02-08Also stopped (terminated): Boehringer Ingelheim, Azacitidine + Volasertib (NCT01957644)
- 2019-02-01Results posted on the registry: Boehringer Ingelheim, BI 6727 + BIBW 2992 (NCT01206816)
- 2019-01-31Results posted on the registry: Boehringer Ingelheim, BI 6727 (NCT01145885)
- 2019-01-31Results posted on the registry: Boehringer Ingelheim, BI-6727 + BI 6727 (NCT00969761)
- 2019-01-31Results posted on the registry: Boehringer Ingelheim, decitabine iv + volasertib iv infusion (NCT02003573)
- 2019-01-31Also stopped (terminated): Boehringer Ingelheim, decitabine iv + volasertib iv infusion (NCT02003573)
- 2018-08-06Results posted on the registry: Boehringer Ingelheim, Volasertib, low dose, d1q3w + Volasertib, middle dose, d1q3w (NCT01348347)
- 2018-07-30Results posted on the registry: Boehringer Ingelheim, BI 6727 + BIBF 1120 (NCT01022853)
- 2018-07-30Results posted on the registry: Boehringer Ingelheim, Azacitidine + Volasertib (NCT02201329)
- 2018-07-30Results posted on the registry: Boehringer Ingelheim, Volasertib (NCT01662505)
- 2018-07-30Results posted on the registry: Boehringer Ingelheim, volasertib (NCT01971476)
- 2018-05-04Also stopped (withdrawn): Massachusetts General Hospital, Volasertib + Cytarabine (NCT02905994)
- 2018-02-28Also stopped (terminated): University of Ulm, Volasertib + Cytarabine (NCT02198482)
- 2017-12-22Also stopped (withdrawn): Yale University, volasertib + belinostat (NCT02875002)
- 2017-11-22Results posted on the registry: Boehringer Ingelheim, BI 6727, IV infusion (NCT01023958)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision